Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2009. The report details a strategic divestment of US commercial rights for the antidepressant Wellbutrin XL to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation.
Key Financial Metrics
- Transaction Value: $510 million (£340 million) for the divestment of US rights to Wellbutrin XL.
- Expected Gain: GSK anticipates recording a pre-tax gain of approximately £340 million in Other Operating Income.
- Projected Income: The combined total of Other Operating Income and profit on disposal of interests in associates is now expected to be around £700 million for 2009.
- Product Sales (Q1 2009): US sales of Wellbutrin XL were £45 million; non-US sales were £7 million.
Material Changes
- Sales Decline: US sales of Wellbutrin XL in the first quarter of 2009 decreased by 70% compared to the prior period, attributed to generic competition that began in late 2006 for the 300mg tablet and Q2 2008 for the 150mg tablet.
- Portfolio Restructuring: GSK is actively reshaping its US business to maximize asset value and redirect resources toward new products and upcoming launches.
Outlook, Risks, and Management Commentary
Management views this transaction as part of a series of actions to optimize the product portfolio. GSK will retain rights to Wellbutrin XL for countries outside the US (excluding Canada) and will transfer the US NDA and trademark license to Biovail. The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2008 Annual Report on Form 20-F.
Investor Verification Checklist
- Confirmation of Hart-Scott-Rodino regulatory clearance for the Biovail transaction.
- Verification of the £340 million pre-tax gain recognition in the next quarterly financial report.
- Assessment of the impact of the 70% sales decline on overall North American Pharmaceuticals revenue.
- Review of the remaining non-US Wellbutrin XL portfolio performance (£7 million in Q1 2009).